



ASX & Media Release

Deoxymab 3E10 lead candidate confirmed

Melbourne, Australia; April 19, 2017: Patrys Limited (**ASX: PAB**), a therapeutic antibody development company, is pleased to announce that it has selected a lead candidate in its Deoxymab 3E10 program to progress into a range of *in vivo* pre clinical cancer models.

The lead candidate, to be known as PAB-DX1, was selected from a large number of 3E10 variants that Patrys designed to optimise for efficacy, manufacturability and novelty. The selection of PAB-DX1 was based on its performance in a suite of *in vitro* assays conducted in collaboration with the lead inventor of the Deoxymab technology, Dr James Hansen at Yale University in the USA. PAB-DX1 outperformed other variants in its ability to penetrate into cells' nuclei, and also to kill cancers cells. Significantly, PAB-DX1 outperformed native forms of the 3E10 antibody in the screening assays.

The confirmation of PAB-DX1 as lead candidate allows Patrys to move forward with the production of antibody to be used in a range of animal models of cancer over the coming months. Data from the first of these models should be available in Q3 2017.

"We are delighted that we have been able to create a novel and highly potent form of Deoxymab 3E10 to progress through development," said Dr James Campbell, Chief Executive Officer and Managing Director of Patrys. "This is a significant milestone for the company, and is a key step as we progress an exciting early stage discovery into a compelling clinical asset. We are excited about the data we have seen so far, and look forward to moving the PAB-DX1 program forward."

About Deoxymab 3E10

Patrys has a worldwide license to develop and commercialise as anti-cancer agents a portfolio of pre-clinical novel anti-DNA antibodies and antibody fragments/variants discovered at Yale University.

Deoxymab 3E10 is an autoantibody originally identified in models of lupus. Whilst most antibodies bind to markers on the surface of cells, Deoxymab 3E10 penetrates cell nuclei, binds directly to DNA, and inhibits DNA repair and causes damage to accumulate. Normal cells can repair such DNA damage, but Deoxymab 3E10 kills cells that have mutations or deficiencies in DNA repair mechanisms that are found in various cancer cells. As well as showing single agent therapeutic potential Deoxymab 3E10 has been shown to significantly enhance the efficacy of both chemo- and radiotherapies.

Patrys believes that Deoxymab 3E10 may have application across a wide range of malignancies such as gliomas, melanomas, prostate, breast, pancreatic and ovarian cancers.

-Ends-



For further information, please contact:

Patrys Limited:

James Campbell
Chief Executive Officer
P: +61 3 9670 3273
info@patrys.com

Patrys IR:

Kyahn Williamson
Buchan Consulting
P: +61 3 9866 4722
kwilliamson@buchanwe.com.au

Patrys Media:

Kellie Stanborough
Buchan Consulting
P: +61 3 9866 4722
kstanborough@buchanwe.com.au

About Patrys Limited:

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of antibodies as therapies for a range of different cancers. Patrys has a pipeline of anti-cancer antibodies for both internal development and as partnering opportunities. More information can be found at www.patrys.com.